Experimental Drug Daraxonrasib Doubles Survival Time in Metastatic Pancreatic Cancer Trial

At the 2026 American Society of Clinical Oncology (ASCO) annual meeting, a standing ovation greeted what many experts are calling the most significant breakthrough in pancreatic cancer treatment in decades. Revolution Medicines presented full data from its Phase 3 clinical trial for daraxonrasib, an experimental daily pill that targets the genetic mutations driving the vast majority of pancreatic tumors. The results demonstrated that the drug effectively doubled the median overall survival for patients with previously treated metastatic pancreatic cancer compared to standard chemotherapy. In a field where progress is typically measured in weeks, the addition of more than half a year of life expectancy represents a seismic shift in gastrointestinal oncology.[1][2]

Pancreatic cancer has long been considered one of the most intractable and lethal malignancies in human biology. Because the pancreas is located deep within the abdomen, tumors rarely cause symptoms until the disease has already spread, or metastasized, to other organs like the liver or lungs. By the time of diagnosis, surgical removal is often impossible, leaving patients reliant on systemic treatments. The five-year relative survival rate for metastatic pancreatic cancer hovers around a dismal 3%, and the standard of care has heavily relied on highly toxic intravenous chemotherapy regimens that offer only marginal extensions of life.[3]

The data presented at ASCO stemmed from the RASolute 302 trial, a global, randomized Phase 3 study that enrolled 500 patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). All participants had previously received at least one line of standard chemotherapy and had seen their cancer progress. Patients were randomly assigned to receive either the once-daily oral daraxonrasib or a second-line chemotherapy regimen chosen by their physician. The trial was designed to definitively answer whether targeting the cancer's underlying genetic driver could outperform the broad, systemic cytotoxicity of traditional chemotherapy.[1][2][3]

The primary endpoint of the trial, median overall survival, delivered a stark contrast between the two study arms. Patients receiving daraxonrasib achieved a median overall survival of 13.2 months, compared to just 6.7 months for those in the chemotherapy control group. This translates to a hazard ratio of 0.40, meaning the experimental drug reduced the risk of death by 60% compared to the current standard of care. For oncologists accustomed to incremental gains, crossing the one-year survival threshold in a second-line metastatic setting is an unprecedented milestone.[1]

Beyond extending life, daraxonrasib also demonstrated a profound ability to halt the progression of the disease. The trial's key secondary endpoint, progression-free survival (PFS), measured how long patients lived without their tumors growing or spreading. The median PFS for patients on daraxonrasib was 7.2 months, exactly double the 3.6 months observed in the chemotherapy arm. This indicates that the drug not only keeps patients alive longer but maintains control over the tumor's biological machinery for a significantly extended period.[2][3]

The scientific achievement behind daraxonrasib is rooted in its ability to target the RAS family of proteins. Mutations in the KRAS gene are found in approximately 90% of all pancreatic ductal adenocarcinomas, acting as an "always-on" switch that commands the cells to divide and multiply uncontrollably. For nearly four decades after its discovery, the KRAS protein was deemed "undruggable" by pharmaceutical chemists because its smooth, spherical surface lacked the deep pockets necessary for traditional small-molecule drugs to bind and take effect.

Daraxonrasib overcomes this historical hurdle through a novel mechanism of action. It is classified as a RAS(ON) multi-selective, noncovalent tri-complex inhibitor. Instead of trying to bind directly to the elusive KRAS protein alone, the drug first attaches to a highly abundant chaperone protein in the cell called cyclophilin A. This newly formed complex then binds tightly to the active, GTP-bound state of the RAS protein, effectively blocking it from interacting with downstream effectors and shutting off the oncogenic signaling pathway.[1][2]

Crucially, daraxonrasib is "multi-selective," meaning it does not just target one specific mutation. Earlier breakthroughs in RAS inhibition, such as sotorasib, only targeted the KRAS G12C mutation, which is common in lung cancer but accounts for only about 1% to 2% of pancreatic cancers. Daraxonrasib is designed to inhibit a wide spectrum of KRAS mutations—including G12D, G12V, and G12R, which dominate the pancreatic cancer landscape—as well as the wild-type (unmutated) version of the protein. The RASolute 302 trial confirmed that the drug was effective across this broad range of genetic profiles.[3]

The safety and tolerability profile of daraxonrasib also marks a significant departure from traditional treatments. Standard chemotherapy attacks all rapidly dividing cells, leading to severe systemic toxicities such as profound fatigue, nausea, hair loss, and dangerous drops in white blood cell counts (neutropenia). In contrast, the adverse events associated with daraxonrasib are primarily driven by its mechanism of action on the skin and mucosal tissues. The most common side effects reported in the trial were rash, stomatitis (mouth sores), and diarrhea.[1][2]

While these side effects require active management by clinical teams, they are generally considered more tolerable than the systemic devastation of chemotherapy. This is reflected in the trial's discontinuation rates: only 1.2% of patients taking daraxonrasib had to stop treatment entirely due to adverse events, compared to 11.2% of patients in the chemotherapy arm. Patient advocacy groups at the ASCO presentation highlighted that individuals on the targeted therapy reported significant improvements in pain management and overall quality of life, allowing them to remain active while undergoing treatment.[3]

Recognizing the urgent unmet need in pancreatic cancer, regulatory agencies are moving rapidly. The U.S. Food and Drug Administration (FDA) previously granted daraxonrasib Breakthrough Therapy designation, a status designed to expedite the development and review of drugs that show substantial improvement over available therapies. Following the release of the topline data, the FDA also authorized an Expanded Access Program (EAP), allowing eligible patients who have exhausted other options and cannot enroll in clinical trials to receive the drug immediately.[1][2]

Revolution Medicines is now preparing to submit a New Drug Application (NDA) to the FDA, utilizing a priority review voucher that could compress the regulatory timeline to just a few months. If approved, daraxonrasib is widely expected to become the immediate standard of care for second-line metastatic pancreatic cancer. However, the company's ambitions extend further. The ongoing Phase 3 RASolute 303 trial is already evaluating daraxonrasib as a first-line treatment, testing it both as a monotherapy and in combination with standard chemotherapy for newly diagnosed patients.[3]

Despite the overwhelming optimism, oncologists caution that daraxonrasib is not a cure. Cancer is highly adaptive, and tumors treated with targeted therapies inevitably develop acquired resistance over time. Researchers are already identifying secondary mutations that allow the cancer cells to bypass the drug's blockade and resume growing. The next frontier in this research will involve identifying the optimal combination therapies—pairing daraxonrasib with other targeted agents or immunotherapies—to cut off these escape routes and extend survival even further.[1][2]

The implications of the RASolute 302 trial extend well beyond the pancreas. Because RAS mutations are the most common oncogenic drivers in human biology, daraxonrasib is also being heavily investigated in other difficult-to-treat malignancies. Clinical trials are currently underway evaluating the drug's efficacy in advanced colorectal cancer and non-small cell lung cancer, where early data has shown promising response rates. The success in pancreatic cancer provides a powerful proof-of-concept for the tri-complex inhibition strategy across solid tumors.[3]

For decades, a diagnosis of metastatic pancreatic cancer has been accompanied by a profound sense of therapeutic nihilism. The ASCO 2026 presentation of daraxonrasib has fundamentally altered that narrative. By successfully drugging a target once thought invincible, and doing so with a daily pill that spares patients the worst ravages of chemotherapy, the oncology community has secured a vital new weapon. As the drug moves toward commercial availability, it represents not just extended months of life, but a beacon of tangible hope for thousands of patients and their families.[1]